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Cytokines control the growth, differentiation, and sur-
vival of cells of the immune system. Since the identifi-
cation of the genes for the T-cell growth factor interleu-
kin-2 (IL-2) and its heterotrimeric receptor (IL-2R), the
important role of cytokines in lymphocyte development
and survival has become increasingly clear. The IL-2
family of cytokines—IL-2, IL-4, IL-7, IL-9, and IL-
15—share both the common g-chain (gc) receptor sub-
unit and much of their intracellular signaling pathways.
These cytokines are critical for normal lymphocyte de-
velopment and peripheral-lymphocyte function. In re-
cent years, important advances in understanding these
receptors and their signaling pathways have contributed
to and built upon the identification of naturally occur-
ring mutations that underlie several inherited forms of
immunodeficiency.
The discovery of both the Janus (Jak) family of ty-
rosine kinases and the family of signal transducers and
activators of transcription (STAT) transcription factors
has provided important insight into the biochemical
mechanism of cytokine signal transduction. On IL-2
binding, Jak1 and Jak3—which are cytoplasmic tyrosine
kinases that constitutively bind to the tails of cytokine
receptor subunits—are activated to phosphorylate the
IL-2R chains. Phosphotyrosine residues in these receptor
chains provide docking sites for STAT proteins, which
are phosphorylated by the Jaks. Once phosphorylated,
the STAT proteins dimerize and translocate to the nu-
cleus, where they activate target genes. This Jak/STAT
mechanism is one of three known pathways through
which IL-2 family members exert their intracellular ef-
fects (fig. 1). The activation of the proliferative and an-
tiapoptotic PI3 kinase pathway and the well-character-
ized Ras pathway are not thought to be responsible for
inherited immunodeficiencies and will not be discussed
here, but they do play an important role in the control
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of IL-2 responses. In this review, we discuss the current
understanding of these cytokine receptors and their sig-
naling pathways, as well as the molecular basis of in-
herited severe combined immunodeficiencies (SCIDs)
that arise from mutations in the genes for the common
gc, the IL-2Ra, the IL-7Ra, and Jak3.
The IL-2R Complex
The discovery of an IL-2–binding, integral membrane
protein (named “IL-2Ra”) that exhibits low-affinity
IL-2 binding (10 nM) but no signaling ability suggested
the existence of a multisubunit IL-2–binding complex.
Subsequently, two proteins that, in combination with the
a-chain, constitute the fully functional, high-affinity (10
pM) IL-2R complex were identified (IL-2Rb and IL-
2Rg). These proteins belong to the cytokine-receptor su-
perfamily, which includes the receptors for many cyto-
kines and interferons (Bazan 1990). Receptors of this
superfamily share receptor subunits, which define spe-
cific subfamilies. For instance, receptors that contain the
common b-chain (bc) bind IL-3, IL-5, or granulocyte
macrophage–colony-stimulating factor, whereas the sub-
family that contains gp130 includes the receptors for
IL-6, oncostatin M, cardiotrophin, IL-11, and others
(Bazan 1990). The IL-2R subfamily is defined by the
presence of the IL-2Rg, or gc (encoded by the gc gene),
which is found in receptors for IL-4, IL-7, IL-9, and IL-
15, as well as in IL-2R (Ihle et al. 1995). Members of
each subfamily bind distinct multisubunit complexes
that share many of their downstream signaling com-
ponents and that, thus, have both pleiotropic and func-
tionally redundant effects (O’Shea 1997).
Both IL-2Rb and gc have four conserved cysteine
residues, membrane-proximal WSXWS motifs in their
extracellular domains, and cytoplasmic domains that
couple the ligand-binding region of the receptors to in-
tracellular effectors. Cytokine receptors, unlike receptor
tyrosine kinases, lack intrinsic phosphotransferase ac-
tivity, but their cytoplasmic domains contain a conserved
membrane-proximal motif known as “box1/box2,”
which is critical for signal transduction from all known
members of the family (fig. 1). The mechanism for signal
transduction through cytokine receptors was first re-
vealed by genetic complementation experiments using
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Figure 1 Signal transduction through the IL-2R complex. Binding of IL-2 to its high-affinity receptor induces the dimerization of IL-2Rb
and gc and activates at least three downstream signaling mechanisms. These mechanisms include a phosphorylation cascade that begins with
the activation of Ras, a lipid kinase (PI-3K) pathway that is permissive for lymphocyte survival, and a third, cytokine-specific signal transduction
pathway, the Jak/STAT pathway. Receptor ligation causes tyrosine phosphorylation and activation of Jak1 and Jak3 and triggers a series of
biochemical events that drive gene transcription via STATs. Recently identified regulatory molecules are shown (yellow).
cells that lacked interferon responsiveness. These cells
could be functionally complemented with the cDNA en-
coding members of the Jak family of kinases (Schindler
and Darnell 1995). Signal transduction through all cy-
tokine receptors depends on one or more Jak family
members (fig. 1) (Ihle et al. 1995).
Four mammalian Jak family members that encode
120–135-kD proteins and that, as a family, exhibit a
high degree of structural similarity, have been described.
Outside of their catalytic domains, Jak proteins show
little homology to other tyrosine kinases. Their catalytic
domains (Janus homology domain 1, or JH1) are found
at their C-termini, adjacent to a “kinase-like” domain,
JH2, that has no detectable kinase activity but that prob-
ably performs a regulatory role (O’Shea 1997). The N-
terminal half of the proteins (i.e., JH3–JH7) is unique
to the Jak family and is thought to be important in
receptor binding (Cacalano et al. 1999).
Three of the mammalian Jak family members—Jak1,
Jak2, and Tyk2—are ubiquitously expressed, whereas
Jak3 is expressed specifically in cells of the hematopoietic
lineage and becomes tyrosine phosphorylated only in
response to cytokines that use gc as a signaling com-
ponent (O’Shea 1997). Jak1 and Jak3 physically asso-
ciate with the IL-2Rb chain and gc, respectively, and
both are activated in response to IL-2, IL-4, IL-7, IL-9,
and IL-15. Jak3 becomes tyrosine phosphorylated only
in response to cytokines that use gc as a signaling com-
ponent. The current dogma regarding signal transduc-
tion through these receptors is that oligomerization of
the receptor components is required to initiate cross-
phosphorylation and activation of Jak kinases, which
lead to the activation of all downstream pathways.
X-Linked SCID
Formal genetic proof that the IL-2R components
are critical for T-cell development came with the iden-
tification of patients lacking either gc or Jak3. These
patients presented with phenotypically identical T/
B/NK SCID (Noguchi et al. 1993; Macchi et al.
1995; Russell et al. 1995). A study of 108 patients
with SCID later revealed that gc deficiency and Jak3
deficiency account for ∼42% and ∼6% of known
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Figure 2 Schematic diagram of Jak3, gc, IL-7Ra, and IL-2Ra,
with mutations that cause SCID. Jak3 mutations affect gc binding
(Y100C), protein-expression levels, and basal or IL-2–inducible ty-
rosine phosphorylation. Mutations in gc also affect Jak3 binding and
signal transduction (R267STOP, L271Q, and A287frameshift). The
two patients with IL-7R defects lack significant mRNA and protein
levels, and the IL-2Ra frameshift results in a nonfunctional protein.
SCID cases, respectively (Buckley et al. 1997). Patients
with Jak3 and gc deficiency have severe defects in T-
cell development and lack peripheral T and NK cells.
Affected infants are characterized by severe, persistent
infections of the upper-respiratory and gastrointesti-
nal tracts, which are caused by common viral (cyto-
megalovirus), fungal (Candida), and bacterial path-
ogens; such infants require allogeneic bone-marrow
transplants in infancy to survive. These patients have
normal to elevated levels of circulating B cells. How-
ever, the B cells are phenotypically immature and non-
functional, presumably as a result of the lack of
helper-T-cell activity, and the patients are usually
hypo- or agammaglobulinemic. The presence of cir-
culating B cells has made it possible to study signaling-
pathway defects directly in Epstein-Barr virus–
transformed B-cell lines derived from the patients.
Of T/B/NK SCID cases, 60%–70% can be mapped
to the Xq13 chromosomal region (Candotti et al. 1998).
Among the criteria used to diagnose X-linked SCID (X-
SCID) is nonrandom X-chromosome inactivation in
lymphocytes from heterozygous female carriers of the
disease. This criterion suggests that cells expressing the
defective allele fail to develop normally, leading to a
preferential expansion of cells that express the wild-type
allele (Uribe and Weinberg 1998). When gc was also
mapped to chromosome Xq13.1, it became an obvious
candidate for X-SCID. This gene consists of eight exons
and spans ∼4.2 kb (Candotti et al. 1998).
Extensive genetic analysis of the molecular lesions in
135 unrelated patients with X-SCID provided some in-
sight into the role of different regions of gc in signal
transduction (Puck 1996). With the exception of two
large deletions, the gc mutations are missense mutations
involving one or a few nucleotides. Genetic analysis has
revealed five mutational hot spots in exons encoding
part of the extracellular domain, the transmembrane do-
main, and the membrane-proximal region of the gc cy-
toplasmic tail. Mutations in one hot spot near the highly
conserved WSXWS residues of the extracellular domain
are thought to interfere with proper folding and ligand
binding (fig. 2). In addition, exon 6, which encodes the
transmembrane domain, and exon 7, which encodes part
of the cytoplasmic tail, also contain clusters of missense
mutations that may disrupt surface expression or impair
coupling to downstream signaling molecules (Puck
1996).
Three atypical cases of X-SCID, in which patients re-
tain some peripheral T-cell function, have been de-
scribed. In one case, a D17N mutation results in a five-
fold decrease in high-affinity IL-2 cell-surface receptors,
although it is unclear whether the mutation directly af-
fects the surface expression or binding activity of the
protein (DiSanto et al. 1994). The second case involves
an L271Q mutation in gc box1, which impairs gc bind-
ing of Jak3, as demonstrated by immunoprecipitation
experiments (Russell et al. 1994). This mutation most
likely disrupts Jak3-dependent signaling through the re-
ceptor. Finally, Kumaki et al. (1999) recently described
a case in which a splice-site mutation causes a 56-amino-
acid substitution in the cytoplasmic tail and confers
weak signaling in response to IL-2.
Autosomal SCID
Jak3-deficient autosomal SCID is phenotypically iden-
tical to X-SCID, but it was identified by a candidate
gene approach, after the discovery of the specific inter-
action between the gc and Jak3. The Jak3 gene on chro-
mosome 19p13.1 spans a region of ∼15 kb and contains
22 exons in humans and 23 exons in mice (Candotti et
al. 1998). Several families that include a female with
SCID or a male with SCID, in whom gc mutations could
be excluded, carry defects in Jak3, and transformed B-
290 Am. J. Hum. Genet. 65:287–293, 1999
cell lines derived from several of these individuals ex-
press little or no Jak3 mRNA or protein (Macchi et al.
1995; Russell et al. 1995).
Several mutated alleles of Jak3 have been isolated and
characterized. Some nonsense or frameshift mutations
result in premature chain termination and represent null
alleles. Other, more subtle mutations still have profound
effects on the function of the kinase (Candotti et al.
1997). Interestingly, Y100C, a missense mutation in
Jak3, which prevents kinase-receptor interaction, resides
in a short stretch of amino acids that are highly con-
served in all members of the Jak family; this finding
suggests an important function for this region in receptor
interaction (Cacalano et al. 1999). The N-termini of Jak
kinases bear homology to the erythrocyte structural-pro-
tein band 4.1. This domain has been found in a vari-
ety of protein kinases and phosphatases in addition to
the ERMS (ezrin/radixin/moesin/schwannomin) pro-
teins, which bind to the cytoskeleton and the plasma
membrane. This portion of Jak3 includes the entire JH7
and JH6 domains, which are critical for receptor binding
(Cacalano et al. 1999). Therefore, the band-4.1 domain
may provide a general mechanism for targeting a func-
tionally diverse group of proteins or signaling molecules
to transmembrane receptors (Girault et al. 1999). Dis-
ease alleles of Jak3 may reduce the level of protein ex-
pression, disrupt kinase activity, or alter basal or IL-
2–inducible tyrosine-phosphorylation levels. Two mu-
tations in the JH2 domain (6-amino-acid deletion at po-
sition 586–592) and one JH3 point mutation (E481G)
markedly decreased the basal and IL-2–inducible tyro-
sine phosphorylation, suggesting that kinase regulation
may be mediated by several domains of Jak3. In contrast,
a single point mutation, C759R, in the JH2 domain re-
sults in high, constitutive Jak3 phosphorylation in the
absence of IL-2. However, in spite of its constitutive
phosphorylation, this molecule fails to signal in response
to IL-2 (Candotti et al. 1998).
In addition to the gc/Jak3 signal-transduction path-
way, lymphoid development has been studied in humans
and mice with defects in individual cytokine pathways.
Several other forms of SCID have been identified, al-
though their molecular lesions have not been character-
ized. Recently, two patients with autosomal recessive
SCID of unknown etiology were reported; the patients
lack T cells but retain both B and NK cells (von Freeden-
Jeffry et al. 1995). The presence of NK cells in these
patients indicated a defect distinct from gc or Jak3 de-
ficiency. Guided by the phenotype of mice with a defi-
ciency of IL-7 and/or IL-7R, Puel et al. (1998) identified
multiple defects in the IL-7Ra gene, as well as in very
low IL-7Ra mRNA and protein expression in these in-
dividuals (fig. 2). Curiously, deficiency in IL-7R had a
very specific effect on T-cell development, although it is
dispensable in the development of NK cells. Thus, the
defects in T-cell development seen in gc- and Jak3-de-
ficient SCID are primarily due to loss of signaling
through the IL-7R. NK-cell survival, on the other hand,
depends on signaling through the IL-15R, a heterotri-
meric complex that contains both gc and IL-2Rb, as well
as a ligand-specific binding chain. Survival signals
through the IL-7R result in the activation of the antia-
poptotic effects of bcl-2. Consistent with this idea, en-
forced expression of bcl-2 can rescue T-cell development
in mice deficient for both IL-7 and gc, but it cannot
rescue NK-cell development, thereby demonstrating the
requirement for distinct signaling pathways in the de-
velopment of different lymphocyte lineages (von Free-
den-Jeffry et al. 1997).
Mice with a targeted disruption of the Jak3 or gc gene
have SCID, but crucial differences between their phe-
notypes and those seen in humans with SCID result from
the different roles played by IL-7 in the species. Both
Jak3/ and gc/ exhibit marked reductions in thymus
cellularity, but in contrast to the corresponding diseases
in humans, the remaining thymic T cells in mice develop
normally. Significant numbers of CD4 cells accumulate
in the periphery of these animals as they age, perhaps
because of a murine-specific thymus-derived growth fac-
tor that serves as an alternative ligand for the IL-7R.
That thymic stromal lymphopoietin (TSLP) is a growth
factor for T cells and can activate STAT5 in the absence
of Jak1 or Jak3 activation suggests that it can sustain
some T-cell development via a gc/Jak3-independent
pathway. Furthermore, unlike humans with gc- and
Jak3-linked SCID, these gene-targeted mice have defec-
tive B-cell development. B-cell development in these an-
imals arrests between the pro–B- and pre–B-cell stages,
indicating that IL-7 is a key factor in B-cell development
in mice but not in humans. These mice also lack NK
cells, intraepithelial gdT cells, dendritic epidermal T
cells, and peripheral lymph nodes, and they have a
marked reduction in the size of their mesenteric lymph
nodes as well. Interestingly, the surviving T cells in these
mice, like those in the IL-2Ra and IL-2Rb gene-targeted
mice, have an activated phenotype, yet they fail to pro-
liferate in response to concanavalin A or anti-CD3, and
they produce very little IL-2 in response to mitogenic
stimuli.
Genetic Analysis of the IL-2R
The role of both IL-2 and the IL-2–signaling pathway
in lymphocyte function has been studied, by phenotypic
analysis, both in gene-targeted mice that lack one of the
components of the IL-2R and in humans with naturally
occurring mutations in the IL-2R genes. Analysis of IL-
2R mutations has revealed that the receptor components
have a number of roles in lymphocyte function: in de-
velopment, in proliferation, and in the control of sur-
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vival, which can lead to down-regulation of the immune
response.
Targeting the genes encoding IL-2, IL-2Ra, and IL-
2Rb has shown that IL-2 signaling is not essential for
either B- or T-cell development, since each mutant strain
develops normally for the first 3–4 wk of life. Thymi of
the young mice contain the normal ratio of CD4 cells
to CD8 cells, with normal cellularity. However, these
mice develop very similar immune disorders, character-
ized by markedly elevated serum immunoglobulin levels
and an often fatal hemolytic anemia. Surviving mice
develop severe inflammatory bowel disease, splenomega-
ly, and lymphadenopathy. Lymph-node T cells from
these mice exhibit a morphology and surface-mark-
er–expression profile that are characteristic of activated/
memory T cells. In spite of their activated phenotypes,
lymph-node T cells from IL-2Rb knockout mice do not
respond to such polyclonal activators as PMA, iono-
mycin, or concanavalin A.
The proliferative defect in IL-2Ra/ mice is less se-
vere, probably because of the presence of signaling-com-
petent, cell-surface IL-2Rbg heterodimers, but prolifer-
ation is decreased in these mice as well. T cells from
IL-2Rb knockout mice cannot mount normal antibody
titers to challenge with vesicular stomatitis virus (VSV),
nor do they generate normal cytotoxic responses to VSV-
infected macrophages. The activated T-cell phenotype
and inflammatory disease are thought to be due pri-
marily to failure to trigger apoptosis in the activated
cells, by maintenance of high levels of bcl-2 expression
(O’Shea 1997). T cells apparently fail to delete after
activation, resulting in exhaustive B-cell activation, hy-
pergammaglobulinemia, and massive lymphocytic and
granulocytic infiltration of such organs as the colon. In
support of this idea is the finding that, in mice lacking
the IL-2Ra chain, there is a striking lack of T-cell de-
letion in response to bacterial superantigens (O’Shea
1997).
In addition to the mouse models for IL-2 signaling
deficiencies, a naturally occurring mutation in the
IL2RA gene in humans has been identified. Its pheno-
type is similar to that of mice with a deficiency of IL-
2Ra and is characterized by increased susceptibility to
bacterial, viral, and fungal infections; massive lympho-
cytic infiltration of many organs; and severe colitis. In
addition, bcl-2 expression in thymocytes was markedly
enhanced in the IL-2Ra patient compared with normal
controls, thereby supporting a model of defective apop-
tosis in activated T cells (Sharfe et al. 1997). This finding
seems paradoxical, since it is known that IL-2 stimu-
lation increases cellular levels of bcl-2. However, sig-
naling through the IL-2R can induce molecules that in-
hibit cytokine responses and, perhaps, the inability to
induce either inhibitors or apoptosis in the gene-targeted
mice results in the severe autoimmune phenotypes.
Clearly, the IL-2R affects the physiology of the immune
response on many levels, acting as a regulator of the
delicate balance between lymphocyte activation and
deletion.
Interestingly, IL-4Ra mutations may predispose pa-
tients to an allergic disease known as “atopy.” This dis-
order is characterized by an immediate hypersensitivity
IgE-antibody response to specific allergens (hyper-IgE
syndrome) and allergic inflammatory skin disease, a con-
dition very similar to the phenotype of IL-4 transgenic
mice. However, patients who have atopy have normal
levels of IL-4, which suggests the presence of mutations
of the IL-4R.
One patient with atopy was found to carry a GrA
transition at nucleotide 1902 of IL-4Ra, which caused
a Q576R substitution in the cytoplasmic domain of
the IL-4Ra. This mutation results in enhanced sig-
naling, possibly because the variant IL-4Ra chain fails
to recruit SHP-1 (see the section on Recent and Forth-
coming Discoveries in Cytokine Signal Transduction,
below) efficiently (Hershey et al. 1997). The R576
allele was common among patients with allergic in-
flammatory disorders, and it segregated strongly in
patients with atopy. The R576 allele was found in
three of three patients with the hyper-IgE syndrome
and in four of seven patients with severe atopic der-
matitis. The mutation was also found in 13 of 20
subjects with elevated serum IgE levels, but it was seen
in only 5 of 30 normal, asymptomatic individuals
from a pool of 50 randomly chosen, unrelated adults.
The overall allelic frequency of the Q576R mutation
in the population of chromosomes was calculated to
be 20%: 35% in patients with atopy and 10% in
normal, asymptomatic subjects. The prevalence of this
mutation suggests that it may contribute significantly
to the high incidence of atopy, which affects 40%
of the population.
Cytokine Signals and Transcriptional Regulation
Detailed functional and biochemical dissection shows
that IL-2Rb has six tyrosine residues that are phospho-
rylated on IL-2 stimulation. Y338 has been shown to
stimulate proliferative signals via the MAP kinase path-
way (fig. 1) (Friedmann et al. 1996), whereas Y392 and
Y510 serve as docking sites for STAT5 proteins. These
tyrosine residues are thought to be responsible for ac-
tivation of the individual signaling pathways that are
briefly outlined below.
Specificity of STAT-receptor interaction is determined
by the sequence of the tyrosine-containing motif on the
receptor (Hoey and Grusby 1999). STAT5a and STAT5b
are recruited to the phosphorylated residues Y392 and
Y510 of IL-2Rb via their conserved SH2 domains. After
Jak-mediated phosphorylation of the C-terminal STAT
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tyrosine residues, the two STAT proteins interact recip-
rocally, by SH2-phosphotyrosine, to form a dimer that
releases from the signaling complex and that translocates
to the nucleus. There, the dimer binds specific, conserved
promoter sequences that are collectively known as
“GAS” (interferon-gamma–activated sequences).
Mice deficient for both STAT5a and STAT5b exhib-
it a profound defect in proliferation of peripheral T
cells, although T-cell development proceeds normally
(Teglund et al. 1998). In addition, STAT5b/, but not
STAT5a/, knockout mice lack NK cells, a finding that
is consistent with evidence that IL-15–induced STAT5b
activation is required in NK-cell development (Teglund
et al. 1998). The nonequivalence of STAT5a and
STAT5b is surprising because these two proteins, which
are encoded on closely linked genes on human chro-
mosome 7q11.2, are 95% identical. Nonetheless, indi-
vidual STAT gene knockouts have quite distinct effects
on the immune system. Because of multiple defects that
occur during development, STAT3 gene disruption is em-
bryonic lethal in mice; however, by use of the cre-lox
system with expression of cre under the control of a T-
cell–specific promoter, a conditional STAT3 knockout
has been generated, which lacks STAT3 expression only
in T cells. These animals show some loss of anti-CD3
and IL-2–induced proliferation, at least partially as a
result of a defect in IL-2Ra–chain expression. This phe-
notype, which is also seen in STAT5a/ mutants, can
be overcome by treating the cells with high concentra-
tions of IL-2, which suggests there is some functional
overlap between STAT3 and STAT5a in IL-2–induced
proliferation.
Recent and Forthcoming Discoveries in Cytokine
Signal Transduction
Recent work has suggested that a number of proteins
may be involved in the control of STAT-mediated tran-
scriptional activation (fig. 1). A 45-kDMyc-binding pro-
tein, Nmi, can associate with STAT5 and may play a
role in modulating many cytokine and interferon re-
sponses, including IL-2 (Zhu et al. 1999). Another family
of proteins, PIAS (protein inhibitor of activated STAT),
interacts with and specifically inhibits the DNA binding
activity of STAT molecules. PIAS3 associates with
STAT3 in response to IL-6, ciliary neurotrophic factor,
and oncostatin M, and the interactions appear to be
specific, since PIAS1 is not coprecipitated with STAT2
or STAT3 and since PIAS3 does not associate with
STAT1 (Chung et al. 1997). The exact mechanism by
which these proteins affect STATs requires further study.
Recently, the protein tyrosine phosphatase SHP-1 has
been reported to be recruited to the IL-2R in a ligand-
dependent manner. SHP-1 can dephosphorylate both
Jak1 and IL-2Rb, and its expression in IL-2–responsive
cells markedly reduces the steady-state phosphorylation
levels of both Jak1 and Jak3. Moreover, constitutive ac-
tivation of the IL-2 signaling pathway has been observed
in human T-cell leukemia virus-1–transformed T cells
and in Sezary syndrome (O’Shea 1997), with an asso-
ciated loss of SHP-1 expression (Migone et al. 1998).
This is interesting, because peripheral T cells from SHP-
1–deficient, “moth-eaten” mice exhibit enhanced pro-
liferation to mitogens and IL-2, which further suggests
that SHP-1 has an important role in the control of
proliferation.
Another family of cytokine-induced inhibitory pro-
teins, reported by several groups, includes variously
named suppressors of cytokine signaling (SOCS), cy-
tokine-induced SH2 proteins (CIS), or STAT-induced
STAT inhibitors (SSI). SOCS-1 was cloned because of
its ability to inhibit IL-6–mediated differentiation of
a myeloid cell line, M1 (Endo et al. 1997; Starr et al.
1997). The mechanism of cytokine inhibition by
SOCS family members is an area of intense investi-
gation. CIS can inhibit IL-3 and erythropoietin re-
sponses by competing for a receptor phosphotyrosine
residue that serves as a STAT docking site, which sug-
gests that CIS is a direct competitive inhibitor of STAT
activation. On the other hand, SOCS-1 and SOCS-3
inhibit cytokine responses by binding to that catalytic
domain and inhibiting Jak activity. SOCS-3 expres-
sion is rapidly induced in lymphocytes in response to
IL-2 (as are SOCS-1 and CIS) and has been shown to
specifically inhibit IL-2–mediated STAT activation.
Because these proteins may be important in the pro-
gression of T-cell–mediated inflammatory disease,
they will no doubt be subject to intense investigation.
Despite these recent advances, our understanding of
cytokine signaling remains sketchy in several respects.
In particular, the pathways that control T-cell expansion
and apoptosis are not understood in detail. The iden-
tification of novel families of proteins—such as SOCS,
Nmi, and PIAS—that are induced by IL-2, points to an
unexpected degree of complexity in downstream regu-
lation of cytokine responses. The study of these proteins
may shed some light on cross-talk that integrates the
various signaling mechanisms within the cytoplasm, and
it should help to pinpoint biochemical imbalances that
manifest as autoimmune disorders or chronic inflam-
matory diseases.
Finally, the current understanding of cytokine signal-
ing has identified targets for therapeutic intervention.
For example, inhibitors of the Jak/STAT pathway may
be valuable in the treatment of allergic disease, in trans-
plantation therapy, and in the treatment of lymphomas
in which constitutive Jak/STAT activity has been ob-
served. Also, the identification of the genetic defects in
several forms of SCID raises the possibility of therapeutic
intervention with a gene-therapy approach. Studies in
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mice have proved that retroviral-mediated transduction
of the wild-type genes for gc and Jak3 rescues lympho-
cyte development and immune function in mice that are
deficient for gc- and Jak3. Perhaps this approach will
be feasible for human immunodeficiencies.
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